Clinical Trial Update: Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating donor-derived allogeneic mesenchymal stem cell injections for refractory graft-versus-host disease. The study also lists dry e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease
• Graft-versus-host Disease

Drugs mentioned

• Allogeneic mesenchymal stem cell (MSC) injection therapy (allogeneic mesenchymal stem cell therapy)

Snippet

Sponsor: Instituto de Investigación Biomédica de Salamanca | Conditions: Dry Eye Disease (DED), Graft-Versus-Host Disease(GVHD) | Phase 2 | Status: NOT_YET_RECRUITING